Albright VAJohnson EO. Emerging topics and innovative methodologies in cannabis research. Subst Abuse 2018;12:1178221818774264.
Allan GMFinley CRTon J. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018;64:e78–e94.
Carliner HBrown QLSarvet AL. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med 2017;104:13–23.
Śledziński PZeyland JSłomski R. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med 2018;7:765–775.
Bubis LDDavis LMahar A. Symptom burden in the first year after cancer diagnosis: an analysis of patient-reported outcomes. J Clin Oncol 2018;36:1103–1111.
Parmar JRForrest BDFreeman RA. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res Social Adm Pharm 2016;12:638–654.
- Search Google Scholar
- Export Citation
)| false . , Parmar JR , Forrest BD Freeman RA Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. 2016; 12: 638– 654. 26443472 10.1016/j.sapharm.2015.09.002
De Petrocellis LOrlando PMoriello AS. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 2012;204:255–266.
Davis MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs 2014;23:1123–1140.
Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 2016;14:915–922.
Godlewski GOffertáler LWagner JA. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 2009;89:105–111.
Ryberg ELarsson NSjögren S. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092–1101.
Kaur RAmbwani SRSingh S. Endocannabinoid system: a multi-facet therapeutic target. Curr Clin Pharmacol 2016;11:110–117.
Castaneto MSGorelick DADesrosiers NA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12–41.
Steele GArneson TZylla D. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep 2019;21:10.
Lucas CJGalettis PSchneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84:2477–2482.
Hui DBruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J Pain Symptom Manage 2017;53:630–643.
Bruera EKuehn NMiller MJ. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6–9.
Lapham GTLee AKCaldeiro RM. Frequency of cannabis use among primary care patients in Washington State. J Am Board Fam Med 2017;30:795–805.
Pergam SAWoodfield MCLee CM. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017;123:4488–4497.
Braun IMWright APeteet J. Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: a nationally representative survey study. J Clin Oncol 2018;36:1957–1962.
Mücke MWeier MCarter C. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle 2018;9:220–234.
Belle-Isle LWalsh ZCallaway R. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy 2014;25:691–699.
Brenneisen RMeyer PChtioui H. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem 2010;396:2493–2502.
- Search Google Scholar
- Export Citation
)| false . , Brenneisen R , Meyer P , Chtioui H Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. 2010; 396: 2493– 2502. 10.1007/s00216-009-3431-3 20112012